ARLG MEMBER, KERRY LAPLANTE, NAMED DEAN OF THE UNIVERSITY OF RHODE ISLAND COLLEGE OF PHARMACY
Kerry LaPlante, PharmD, FCCP, FIDSA, FIDP has been named Dean of the University of Rhode Island (URI) College of Pharmacy. Dr. LaPlante, a member of both the ARLG Pharmacokinetics Working Group and the ARLG Diagnostics Subcommittee, will be the first woman to serve as Dean, beginning her tenure January 2024. In her career as a ...Read moreROBIN PATEL, MD APPOINTED TO THE PRESIDENTIAL ADVISORY COUNCIL ON COMBATING ANTIBIOTIC-RESISTANT BACTERIA
Robin Patel, MD, Director of ARLG’s Laboratory Center, has been named a Voting Member of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (PACCARB). PACCARB is a federal advisory council that provides advice, information, and recommendations to the President’s Secretary of Health and Human Services (HHS) regarding the fight against antimicrobial resistance (AMR) in the ...Read moreARLG INNOVATION AND EVOLUTION SUPPLEMENT PUBLISHED IN CLINICAL INFECTIOUS DISEASES JOURNAL
The ARLG has published a new supplement in Clinical Infectious Diseases (CID) that features ARLG’s scientific accomplishments and future directions (Volume 77, Supplement 4, 15 October, 2023). As part of the Infectious Disease Society of America’s (IDSA) family of journals, the focus of CID is presenting novel research, reviews, and perspectives about all aspects of ...Read moreARLG PARTNERS WITH BIOMEME ON STUDY OF NEW DIAGNOSTIC TOOL TO TACKLE AR
As part of ARLG’s Scientific Agenda to prioritize clinical research focused on novel diagnostics, a new partnership with Biomeme, an innovative biotechnology company, centers on studying a host response test to quickly differentiate between bacterial and viral infections. The goal of the Rapid Diagnostic in Categorizing Acute Lung Infections, (RADICAL 510k) Study is to evaluate the ...Read more
ARLG in the News
As Superbugs Flourish, Bacteriophage Therapy Recaptures Researchers’ Interest, JAMA Network, February 22, 2023
Adaptive Phage Therapeutics Announces First Patient Dosed in the PHAGE Clinical Trial Evaluating Phage Therapy in Cystic Fibrosis-related Respiratory Infection, January 12, 2023
Study Evaluates Biomarker to Help Curb Unnecessary Antibiotic Use, December 13, 2022
NIH-Supported Clinical Trial of Phage Therapy for Cystic Fibrosis Begins, October 4, 2022
Dr. Robin Patel Selected for 2022 Hamao Umezawa Memorial Award, March 8, 2022
Local VA Infectious Disease Expert Selected to Lead Emerging Infectious Diseases Response, March 2, 2022
Duke doctor: Superbugs are the next pandemic. What the US must do to combat them. Op-ed, Raleigh News & Observer, Charlotte Observer, Durham Herald-Sun. January 20, 2022
Adaptive Phage Therapeutics Announces Strategic Agreement with ARLG to Support Phase 1b/2 Cystic Fibrosis Study, November 2, 2021
Carbapenem-resistant Enterobacterales in the USA, March 6, 2020
Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study, March 6, 2020
NIH Renews Funding for the Antibacterial Resistance Leadership Group, NIAID, December 13, 2019
Research Network Based at DCRI Awarded up to $102.5M for Work on Antibacterial Resistance, DCRI, December 13, 2019
Duke Clinical Research scores $102.5M federal award for its work on antibacterial resistance, WRAL TechWire, December 2019.
Duke Clinical Research Institute lands $100M+ federal contract, Triangle Business Journal, December 2019.
Licensing Nucleic Acid Amplification Tests for Extragenital Gonorrhea and Chlamydia: Innovative Science and a Call to Arms. Clinical Infectious Diseases editorial authors praise the ARLG MASTER-GC study for its clinical relevance and collaborative approach to the development of diagnostics. November 2019.
Reviewing data collected by the ARLG, FDA clears first diagnostic tests for extragenital testing for chlamydia and gonorrhea, FDA, May 23, 2019
The ARLG and COMBACTE join forces to create gloabal alliance against antibiotic resistance, DCRI, April 13, 2019
Antibiotic Resistance in the News
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis, The Lancet, January 19, 2022
Pull Incentives for Antibiotics: How Much and Why? April 2020
IDWeek announces new June 18 deadline extension for abstract submissions April 2020
Antibiotic resistance: the hidden threat lurking behind COVID-19 March 2020
Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization February 2020
Centers for Disease Control and Prevention releases its 2019 Antibiotic Resistance Threats Report, CDC November 2019
Wellcome Trust releases report on Reframing Resistance—How to communicate about antimicrobial resistance effectively, October 2019
Too many people use antibiotics improperly, which can pose risks, (featuring Vance Fowler, MD) Washington Post, September 16, 2019